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Abstract
Background Does below-knee symptomatic muscular
(gastrocnemius or soleus) vein thrombosis (MVT) warrant
investigation and treatment in post-operative orthopaedic
patients? We performed a literature search and evaluated
the evidence looking for guidance regarding this question.
Materials and methods We performed a literature search
with the use of PubMed, Medline and Google Scholar from
1950 to September 2011. Search terms included ‘‘muscular
vein thrombosis’’ (MVT) and ‘‘isolated gastrocnemius or
soleus vein thrombosis’’ (IGSVT). We reviewed the eight
level II studies relevant to our search, only one of which
was in a specific orthopaedic population.
Results Studies looking at the rates of progression of
isolated MVT have shown conflicting results. There is also
a lack of consensus between studies that compare pro-
gression amongst groups with or without anticoagulant
treatment. The majority of the studies do not distinguish
between medical, surgical or orthopaedic patients.
Conclusions We cannot confidently recommend com-
mencement of anticoagulation treatment upon identifica-
tion of MVT in post-operative orthopaedic patients. We
can only suggest that, once MVT is diagnosed, the patient
should undergo serial ultrasound scan (USS) duplex scans,
and if propagation is identified, then treatment may be
deemed beneficial.
Level of evidence: III (review of non-randomized con-
trolled cohort/follow-up studies).
Keywords Muscular vein thrombosis  Orthopaedic 
Anticoagulation treatment  Isolated gastrocnemius or
soleus calf vein thrombosis
Introduction
Does below-knee symptomatic muscular vein thrombosis
(MVT) warrant investigation and treatment in post-opera-
tive orthopaedic patients?
MVT and isolated gastrocnemius or soleus vein throm-
bosis (IGSVT) are often interchangeable terms used to
describe thrombosis in the superficial veins of the soleus
and gastrocnemius muscles of the calf. There is little
agreement in the literature and clinical practice as to
whether MVT should be classed as deep or superficial vein
disease and thus whether the treatment falls into the current
guidelines for deep vein thrombosis (DVT) or not. We
noted that in some centres, when DVT is suspected, the
below-knee muscular veins are routinely imaged during
Doppler ultrasound, whilst in others they are not. This
discrepancy has significant consequences for the patient,
since current guidelines derived from the Cochrane Col-
laboration [1] recommend treatment of DVT with imme-
diate subcutaneous low-molecular-weight heparin and then
oral anticoagulation with warfarin for 3 months unless
contraindicated. Therefore, orthopaedic patients are facing
a lottery, where in some centres they are investigated and
treated for MVT whilst in others they are not. There are
currently no national guidelines as to whether these veins
should be imaged routinely and which treatment patients
should receive if any.
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Thrombotic disease is a very real problem for ortho-
paedic patients; the rate of DVT without prophylaxis may
be as high as 45–51 % [2]. An American study by White
et al. [3] of primary hip (19,586) and knee (24,059)
arthroplasties, of which 80–90 % received chemical pro-
phylaxis, found that the incidence of DVT or pulmonary
embolus (PE) within 3 months was 556 (2.8 %) and 508
(2.1 %), respectively. The figure quoted by the British
Orthopaedic Association (BOA) on its recommended
standardised consent form for total hip arthroplasty is a
2.5 % risk of DVT and\1 % for PE [4]. Warwick et al. [5]
found that the incidence of fatal PE in a group of 1,162
total hip arthroplasties not receiving chemical prophylaxis
was 0.34 %, whilst the rate of DVT was 1.89 %. These
patients received antithrombotic stockings, and early
mobilisation was encouraged. The long-term repercussions
of DVT include post-thrombotic limb syndrome, chronic
venous insufficiency, skin changes, pain, ulcers [6] and
emboli including PE and possibly even death [7]. The
Italian inter-society consensus statement on antithrombotic
prophylaxis states that the incidence of venous thrombo-
embolism (VTE) in Europe is approximately 770,000 [8].
Distal or below-knee or calf vein thrombosis (DVT) refers
to the anterior/posterior tibial, the peroneal veins, i.e. those
that correspond to arterial structures. There are also the
muscular calf (soleus or gastrocnemius) veins, as represented
in Fig. 1. Kearon et al. [9] stated that, although the diagnosis
of above-knee DVT is routinely performed by Doppler
ultrasound scan (USS) with confidence (97 % sensitivity,
98 % specificity), the same cannot be said for below-the-
knee diagnostic powers of this modality (50–75 % sensi-
tivity, 90–95 % specificity). This limited performance of
below-knee venous examination may explain why many
centres investigate above-knee venous systems only.
Materials and methods
We performed a literature search with the use of PubMed,
Medline and Google Scholar from 1950 to September
2011. Search terms included ‘‘muscular vein thrombosis’’
(MVT) and ‘‘isolated gastrocnemius or soleus vein
thrombosis’’ (IGSVT). All potentially relevant articles
were retrieved and reviewed. Reference lists of the selected
articles were reviewed, and pertinent publications were
also included. Eight level II studies were found to have
been conducted on MVT, one of which on orthopaedic
patients alone.
In our review of the literature, we sought evidence for
and against the treatment of MVT as an entity along with
evidence for and against treatment in orthopaedic patients.
For the purpose of this paper, MVT is defined as com-
bined thrombosis of gastrocnemius or soleus calf veins
whereas isolated MVT refers to an isolated thrombosis of




Gillet et al. [10] showed in a prospective level II study of
128 outpatients with isolated MVT that 29 cases developed
further venous thromboembolic disease in a 36-month
study period. Thrombus in above-knee deep veins occurred
in 23 patients and pulmonary emboli in 6 patients. This
paper does not distinguish between surgical and medical
patients or their conditions.
MacDonald [11] studied the progress of 135 MVTs
across all specialties in a prospective case series and found
that the rate of propagation of MVT to the level of the
popliteal vein was 3 %. All patients in whom this was the
case had been diagnosed with cancer. Propagation in 90 %
occurred within the first 2 weeks after diagnosis. None of
these MVTs developed to involve a deep vein of the thigh
or cause PE. Labropoulos et al. [12] concluded that the risk
of propagation of soleus and gastrocnemius vein throm-
bosis to above-knee DVT was similar to that of posterior
tibial and peroneal veins in their study of 48 patients,
Fig. 1 Schematic of distal calf veins (deep and muscular)
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suggesting that MVT is perhaps of similar significance to
other below-knee DVTs.
A prospective study of 84 consecutive patients with
isolated MVT by Schwarz et al. [13] compared two cohorts
of patients, one receiving treatment and the other not.
Patients were monitored for thrombosis propagation with
Doppler imaging, and it was found that in those treated for
10 days with heparin the rate of propagation was 25 % less
than in those who were not (95 % confidence interval,
11.5–43.4 %). They had no cases of major haemorrhage in
the group treated with anticoagulation. This study however
did not distinguish between medical, surgical or ortho-
paedic patients. Sales et al. [14] in 2010 found no differ-
ence in 141 patients in the rate of progression of thrombus
in isolated muscular calf vessels when comparing treatment
with no treatment. Again this was in a pooled group of
hospitalised patients. Galanuad et al. [15] compared
3-month outcomes of 222 deep vein thromboses and 390
muscular vein thromboses and found no difference in death
or recurrence of VTE after treatment.
More recently, in 2009, Lautz et al. [16] retrospectively
analysed 38,426 venous duplex scans at one institution
over a 5-year period for patients with isolated IGSVT.
They measured the rate of propagation amongst those
patients who subsequently went on to have a repeat scan
showing deep vein below-knee VTE, above-knee VTE or
PE. This study showed an incidence of VTE of 18.7 %
(DVT 16.3 %, PE 3.9 %, both 1.5 %). The authors found a
significantly higher incidence of VTE in those who were
not treated with therapeutic anticoagulation (no treatment,
30 %; prophylactic treatment, 27 %) when compared with
those who were (12 %). The authors were unable to show
the same association for PE. The analysis was carried out
on 406 patients who were initially diagnosed with IGSVT
and who then returned for subsequent studies. There were a
further 296 patients who were diagnosed with IGSVT who
were excluded from the analysis due to lack of follow-up
(42 % overall). The retrospective nature of this study may
well skew the incidence of propagation, as a huge pro-
portion of patients were never followed up (presumably as
they never subsequently developed a symptomatic VTE).
Inclusion of these patients lost to follow-up could also
significantly alter the incidence of VTE in the three dif-
ferent treatment groups if those lost to follow-up were less
likely to have received treatment for their IGSVT. This
study included all patients presenting for venous duplex
scan.
Muscular vein thrombosis in orthopaedic patients
Wang et al. [17] investigated a group of 359 consecutive
patients in Taiwan who underwent total knee arthroplasty.
All post-operative patients underwent imaging, and 175
patients (49 %) were found to have radiological evidence
of DVT, 38 (22 %) of which were isolated MVT. They
found that 16 (42 %) of the MVTs produced clinical
symptoms but only 1 patient went on to develop propa-
gation to above-knee DVT and none developed PE. Use of
prophylaxis in these patients made no difference to the rate
of late DVT, propagation or PE.
MVT and DVT treatment in orthopaedic patients
Long-term consequences of below-knee DVT were studied
by Masuda et al. [18] in a cohort study of 49 patients.
Approximately half the group had received anticoagulation
therapy for their thrombosis, whilst others had not. The
incidence of propagation for the whole group was 4 % (two
patients), and neither of these patients received thrombo-
prophylaxis. They found that late complications of DVT,
i.e. above-knee propagation and post-thrombotic syn-
drome, are low in all cases of isolated calf vein thrombosis
at 3 years, and there were no cases of clinical PE. They
agreed that, if propagation was to occur, it did so before
14 days.
Oishi et al. [19] studied a cohort of 273 consecutive
orthopaedic patients who underwent total hip or knee
arthroplasty and who received mechanical DVT prophy-
laxis with pneumatic compression stockings. Doppler
imaging was used to detect, and subsequently follow up,
progression of thrombus. Below-knee vein thrombosis
developed in 41 patients (15 %), and all of these were
asymptomatic. At days 7 and 14 post-operatively, they
found that only seven patients (2.5 %) went on to develop
above-knee thrombus, with all but one of these occurring
within 14 days. While this study included all below-knee
DVTs, it did not distinguish MVT separately. This evi-
dence demonstrates that, while there is potential for
thrombus propagation of below-knee DVTs, this usually
occurs within the first 14 days.
A summary of these studies and their findings can be
seen in Table 1.
Discussion
There are potential complications for orthopaedic patients
taking anticoagulation treatment, including haemorrhage
[locally, from the gastrointestinal (GI) tract or intracranially],
infection, wound breakdown, warfarin-induced skin necrosis
[20] and prolonged hospital stay. A study by Saleh et al. [21]
found that haematoma formation and persistent post-operative
drainage increase the risk of superficial surgical-site infection,
and this in turn is strongly related to deep wound infection.
Patel et al. [22] have found that persistent post-operative
drainage is associated with the use of low-molecular-weight
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heparin. An American study by Novicoff et al. [23] published
in 2008 retrospectively examined over 1,000 orthopaedic cases
undergoing total hip or knee arthroplasty over 3 years.
According to local protocol introduced in 2005, all patients
received warfarin starting on the day of surgery and low-
molecular-weight heparin if they were at high risk of throm-
botic disease to continue for 4–6 weeks after surgery. The
implementation of this regimen saw a statistically significant
increase in the rate of complications and length of hospital stay.
Bleeding complications increased from1.4 % in 2004 to 9.6 %
in 2006 (P \ 0.0001). The rate of venous thromboembolism
did not change in this period. The studies that look at com-
plications of anticoagulation for orthopaedic patients focus
largely on prophylaxis rather than treatment regimens. We
speculate that the range and rate of complications may differ
since the treatment dose is higher and for a longer period.
The cost of primary DVT treatment in the UK is
calculated to be £721 [24], including diagnosis, anticoag-
ulation and follow-up. For lifetime treatment of post-
thrombotic limb syndrome, this rises drastically to £3,866,
making treatment of DVT worthwhile. However, the cost
of treating just one episode of major haemorrhage is esti-
mated to be over £10,000 [25]. It is not clear whether the
same long-term consequences apply to MVT when con-
sidered as a separate entity from DVT. Since there is no
uniform classification of MVT, it is unclear whether much
of the data on the risks versus benefit of DVT treatment
apply to MVT or not.
The diagnosis and treatment of DVT for any patient is
significant, with a minimum of 3 months anticoagulation,
regular blood tests, subcutaneous heparin or warfarin with
multiple visits to hospital or clinics. Anticoagulation
treatment in DVT patients is also associated with a major
haemorrhagic risk (0.6–1.2 %) and fatal bleeding
(0.1–0.4 %) over the 3-month treatment period depending
on treatment method [26]. In addition, such patients will be
labelled high risk for further thrombotic events according
to National Institute for Clinical Excellence (NICE)
guidelines [27], meaning that for subsequent admissions
they will always be given chemical prophylaxis. This
would also be the case in other parts of the world where
national guidelines or consensus statements exist regarding
managing the risk of VTE in orthopaedic patients. Another
example of this would be the Italian inter-society consen-
sus statement on antithrombotic prophylaxis [8].
Attached to this diagnostic label is the disadvantage of
being considered a higher risk when determining life and
health insurance. Patients in the USA report having their
monthly premiums doubled on finding they had a DVT [28].
Such a diagnosis will be permanently recorded in the
patient’s medical notes and affect how they are treated on
subsequent hospital admissions. To label MVT as DVT
therefore has significant implications for the patient’s future.
In a review article by Righini et al. [29], prospective
outcome studies for above-knee and complete (above and
below knee) DVT investigations were scrutinised. This
demonstrated that the pooled 3-month thromboembolic risk
of the above knee and the combined (above and below
knee) were similar, stating that detection of calf DVT may
not reduce the 3-month thromboembolic risk but entails a
significant risk of false-positive findings with subsequent
unnecessary anticoagulation.
In summary, studies looking at the rates of progression
of isolated MVT have shown conflicting results. There is
also a lack of consensus between studies that compare
progression amongst groups with or without anticoagulant
treatment. The majority of the studies do not distinguish
between medical, surgical or orthopaedic patients. When
surgical, and in particular lower limb arthroplasty patients
are considered separately, the results may well differ as the
underlying risk factors are quite different. Therefore, the
rate of propagation and long-term effects will also be
affected by this method of patient selection. There are
difficulties in drawing together the evidence that exists to
analyse an overall risk, since the studies use very different
variables such as patient group, timescale, interventions
and investigations.
Considering the absence of national guidelines and
level I evidence, the small number of studies and the well-
documented potential complications of anticoagulation in
the orthopaedic group of patients, MVT should not be
routinely treated. We can only recommend surveillance of
MVT with serial Doppler investigations for a period of no
less than 2 weeks in order to identify those clots which
propagate proximally and to only start anticoagulation
treatment if propagation occurs.
Finally, we suggest that a high level of evidence trial,
such as a randomized control trial, be conducted to ascer-
tain whether diagnosis of MVT in an orthopaedic group of
patients is significant, and if treatment of MVT in ortho-
paedic patients is indicated.
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